The protocol will study the effect of the combination of two drugs-Abraxane and
Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal
cancer. This study drug combination will be given to subjects who have already been treated
for their cancer with other chemotherapy, and now their cancer has become worse or has come
back again. Neither one of these study drugs has been approved by the FDA for treatment in
these three types of cancer.